Most recently, low-dose IL-2 has also been shown to expand or modify CD4+ regulatory T cells in vitro from patients with SLE [13,14] and children with the drug-resistant idiopathic nephrotic syndrome [19]. Here, IL2 is linked to idiopathic nephrotic syndrome.